Anti-Aβ antibodies induced by Aβ-HBc virus-like particles prevent Aβ aggregation and protect PC12 cells against toxicity of Aβ1-40

Journal of Neuroscience Methods

Volumn 218, Issue 1, 2013, Pages 48-54

  Feng, Gaifeng ^a   Wang, Weixi ^a   Qian, Yihua ^a   Jin, Hui ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Amyloid peptide (A ); Immunotherapy; Virus like particles (VLPs)

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; ANTI AMYLOID BETA ANTIBODY; ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; HEPATITIS B VIRUS; IMMUNIZATION; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSMISSION ELECTRON MICROSCOPY; VIRUS LIKE AGENT;

Β-AMYLOID PEPTIDE (AΒ); IMMUNOTHERAPY; VIRUS-LIKE PARTICLES (VLPS);

ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; FEMALE; GENETIC ENGINEERING; HEPACIVIRUS; MICE; MICE, INBRED BALB C; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; RECOMBINANT FUSION PROTEINS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84878952104     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2013.05.006     Document Type: Article

References (43)

1. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005, 174(3):1580-1586.
2. Bach P., Tschape J.A., Kopietz F., Braun G., Baade J.K., Wiederhold K.H., et al. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol 2009, 182(12):7613-7624.
3. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Gemes D., et al. Epitope isotype specificities of antibodies to beta-amyloid for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003, 100(4):2023-2028.
4. Birnbaum F., Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol 1990, 64(7):3319-3330.
5. Chackerian B., Lowy D.R., Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001, 108(3):415-423.
6. Chackerian B., Tangel M., Hunter Z., Peabody D. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine 2006, 24(37-39):6321-6331.
7. Clarke B.E., Newton S.E., Carroll A.R., Francis M.J., Appleyard G., Syred A.D., et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987, 330(6146):381-384.
8. Cribbs D.H., Ghochikyan A., Vasilevlo V., Tran M., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003, 15(4):505-514.
9. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londono-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26(51):6503-6507.
10. Dodel R.C., Du Y., Depboylu C., Hampel H., Frolich L., Haag A., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75(10):1472-1474.
11. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004, 14(1):11-20.
12. Frenkel D., Dori M., Solomon B. Generation of anti-beta-amyloid antibodies via phage display technology. Vaccine 2004, 22(19):2505-2508.
13. Fu H.J., Liu B., Frost J.L., Lemere C.A. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 2010, 9(2):197-206.
14. Geldmacher A., Skrastina D., Borisova G., Petrovskis I., Kruger D.H., Pumpens P., et al. A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the pre-existing anti-core antibodies. Vaccine 2005, 23(30):3973-3983.
15. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64(9):1553-1562.
16. Hardy J.A., Higgins G.A. Alzheimer's disease, the amyloid cascade hypothesis. Science 1992, 256(5054):184-185.
17. Huang X., Wang J., Cui L., Zou X., Zhang Y. Recombinant GST-I-A beta 28-induced efficient serum antibody against A beta 42. J Neurosci Methods 2010, 186(1):52-59.
18. Janus C., Peearson J., Mclaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408(6815):979-982.
19. Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Veremeiko T.A., et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000, 18(4):329-337.
20. Kim H.D., Jin J.J., Maxwell J.A., Fukuchi K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett 2007, 112(1):30-38.
21. Lavie V., Becker M., Cohen-Kupiec R., Vacoby I., Koppel R., Wedenig M., et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 2004, 24(1):105-113.
22. Leverone J.F., Spooner E.T., Lehman H.K., Clements J.D., Lemere C.A. Abeta1-15 is less immunogenic than Abeta 1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting. Vaccine 2003, 21(17-18):2197-2206.
23. Li Q., Cao C., Chackerian B., Schiller J., Gordon M., Ugen K.E., et al. Overcoming antigen masking of anti-amyloid beta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloid beta immunized amyloid precursor protein transgenic mice. BMC Neurosci 2004, 5:21.
24. Maier M., Seabook, Lazo N.D., Jiang L., Das P., Janus C., et al. Short amyloid-β immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer's disease mouse model in the absence of an Aβ-specific cellular immune response. J Neurosci 2006, 26(18):4717-4728.
25. 1-11 antibody binds to different β-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem 2007, 282(31):22376-22386.
26. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001, 98(18):10273-10278.
27. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan C., et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest 2003, 112(3):415-422.
28. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408(6815):982-985.
29. Olkhanud P.B., Mughal M., Ayukawa K., Malchinkhuu E., Bodogai M., Feldman N., et al. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid β-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine 2012, 30(9):1650-1658.
30. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61(1):46-54.
31. Pumpens P., Borisova G.P., Crowther R.A., Grens E. Hepatitis B virus core particles as epitope carries. Intervirology 1995, 38(1-2):63-74.
32. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., et al. 18-Month study of imtravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30(11):1728-1736.
33. Riedl P., stober D., Oehninger C., Melber K., Teimann J., Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol 2002, 168(10):4951-4959.
34. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740):173-177.
35. Schodel F., Moriarty A.M., Peterson D.L., Zheng J.A., Hughes J.L., Will H., et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol 1992, 66(1):106-114.
36. Seabrook T.J., Bloom J.K., Iglesias M., Spooner E.T., Walsh D.M., Lemere C.A. Species-specific immune response to immunization with human versus rodent A beta peptide. Neurobiol Aging 2004, 25(9):1141-1151.
37. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., et al. Dendrimeric Aβ1-15 is an effective immunogen in wildtype APP Tg mice. Neurobiol Aging 2007, 28(6):813-823.
38. Solomon B., Frenkel D. Immunotherapy for Alzheimer's disease. Neuropharmacology 2010, 59(4-5):303-309.
39. Town T., Vendrame M., Patel A., Poetter D., DelleDonne A., Mori T., et al. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol 2002, 132(1-2):49-59.
40. Winblad B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T., et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012, 11(7):597-604.
41. Wisniewski T., Boutajangout A. Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med 2010, 77(1):17-31.
42. Zamora E., Handisurya A., Shafti-Keramat S., Borchelt D., Rudow G., Conant K., et al. Papillomavirus-like particles are an effective platform for amyloid-β immunization in rabbits and transgenic mice. J Immunol 2006, 177(4):2662-2670.
43. Zlotnick A., Cheng N., Conway J.F., Booy F.P., Steven A.C., Stahl S.J., et al. Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry 1996, 35(23):7412-7421.